Advancing inducible gene-inactivation systems to explore synthetic lethality
NAR Cancer · 2026
DOI: 10.1093/narcan/zcag004 ↗Kurz gefasst
Fachartikel in der Zeitschrift NAR Cancer, 2026. Verfasst von Ádám Tamás Sánta und 7 weiteren Autor:innen. Beteiligte Einrichtung: HCEMM-HUN-REN BRC Mutagenesis and Carcinogenesis Research Group, Institute of Genetics, HUN-REN Biological Research Centre, H-6726 Szeged, Hungary. Hauptthemen laut MEDLINE: BRCA1 Protein, DNA-Binding Proteins, Gene Silencing, Synthetic Lethal Mutations. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 114 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Research, Development, and Innovation Office, European Union’s Horizon 2020 research and innovation program.
Abstract (Originalsprache)
Synthetic lethality offers opportunities to identify therapeutic targets for cancer research, facilitating the development of targeted tumour therapy protocols. However, current gene knockout approaches may cause compensatory changes in cellular function and, often, RNAi does not align with the ideal time window for studies and can be inconsistent, limiting the study of molecular interactions, especially when the disruption of two genes causes cell death. To circumvent this problem, we developed the IGIS (Inducible Gene-Inactivation Systems) platform, which uses transient or targeted integration of tetracycline-regulated gene-silencing constructs into human cell lines and fluorescent markers, permitting precise timing of gene inactivation, avoiding transfection variability, and enabling follow-up assays. The applicability of the IGIS systems was validated by investigating the functional interplay between the BRCA1 and RAD18 genes. Combining IGIS with cell survival, DNA fibre, BrdU alkaline comet assays, and pRPA immunostaining, we show that BRCA1 and RAD18 work in different pathways in replication-fork restart and post-replicative gap filling, and thus combined loss of these factors leads to accumulation of ssDNA gaps and replication catastrophe. This synthetic-lethal interaction study with our newly developed IGIS method highlights RAD18-dependent tolerance mechanisms as potential therapeutic vulnerabilities in BRCA-deficient tumours.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- HCEMM-HUN-REN BRC Mutagenesis and Carcinogenesis Research Group, Institute of Genetics, HUN-REN Biological Research Centre, H-6726 Szeged, Hungary.
- Doctoral School of Biology, Faculty of Science and Informatics, University of Szeged, H-6720 Szeged, Hungary.
- Delta Bio 2000 Ltd., H-6726 Szeged, Hungary.
ORCID-Profile: Lajos Haracska
Förderung
- National Research, Development, and Innovation Office
- European Union’s Horizon 2020 research and innovation program
Zitieren
APA
Sánta, Á. T., Gráf, A., Vincze-Kontár, K., Kovács, K., Bóna, B., Mórocz, M., Kiss, E., & Haracska, L. (2026). Advancing inducible gene-inactivation systems to explore synthetic lethality. NAR Cancer. https://doi.org/10.1093/narcan/zcag004
Vancouver
Sánta ÁT, Gráf A, Vincze-Kontár K, Kovács K, Bóna B, Mórocz M, et al. Advancing inducible gene-inactivation systems to explore synthetic lethality. NAR Cancer. 2026. doi:10.1093/narcan/zcag004
BibTeX
@article{Snta2026,
author = {Sánta, Ádám Tamás and Gráf, Alexandra and Vincze-Kontár, Katalin and Kovács, Katalin and Bóna, Bernadett and Mórocz, Mónika and Kiss, Ernő and Haracska, Lajos},
title = {Advancing inducible gene-inactivation systems to explore synthetic lethality},
journal = {NAR Cancer},
year = {2026},
doi = {10.1093/narcan/zcag004}
}
EUVIMED